MedPath

EISAI INC.

EISAI INC. logo
🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

A Study of AQUAVAN® Injection Versus Midazolam HCl for Sedation in Elderly Patients Undergoing Elective Colonoscopy

Phase 2
Terminated
Conditions
Colonoscopy
Colon Polyps
First Posted Date
2005-09-21
Last Posted Date
2023-06-18
Lead Sponsor
Eisai Inc.
Target Recruit Count
100
Registration Number
NCT00209599

A Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux Disease

Phase 3
Completed
Conditions
Non-erosive Gastroesophageal Reflux Disease
Interventions
First Posted Date
2005-09-14
Last Posted Date
2011-10-05
Lead Sponsor
Eisai Inc.
Target Recruit Count
26
Registration Number
NCT00165672

Efficacy and Safety of Donepezil Hydrochloride (Aricept) in Vascular Dementia

Phase 4
Completed
Conditions
Vascular Dementia
Interventions
First Posted Date
2005-09-14
Last Posted Date
2012-05-04
Lead Sponsor
Eisai Inc.
Target Recruit Count
36
Registration Number
NCT00165763
Locations
🇵🇭

Memory Center, Quezon, Manila, Philippines

🇵🇭

Subic Bay Medical Center, Olongapo, Zambales, Philippines

Donepezil Hydrochloride (E2020) in Dementia Associated With Cerebrovascular Disease

Phase 3
Completed
Conditions
Dementia, Vascular
First Posted Date
2005-09-14
Last Posted Date
2011-04-01
Lead Sponsor
Eisai Inc.
Target Recruit Count
974
Registration Number
NCT00165737
Locations
🇺🇸

Neurological Associate of Albany PC, Albany, New York, United States

🇺🇸

St. Francis Medical Center, Peoria, Illinois, United States

🇺🇸

University of Texas Mental Sciences Institute, Houston, Texas, United States

and more 2 locations

A Phase I Open Label Study of E7974 Administered on a Day 1 of 21-Day Cycle In Patients With Advanced Solid Tumors

Phase 1
Completed
Conditions
Cancer, Malignant Tumors
Interventions
First Posted Date
2005-09-14
Last Posted Date
2013-05-22
Lead Sponsor
Eisai Inc.
Target Recruit Count
40
Registration Number
NCT00165802
Locations
🇺🇸

Sylvester Comprehensive Cancer Center - University of Miami, Miami, Florida, United States

🇺🇸

Cancer Institute Of New Jersey, New Brunswick, New Jersey, United States

Maintenance Intermittent Therapy for Symptomatic GERD Patients

Phase 2
Completed
Conditions
Gastroesophageal Reflux Disease
Interventions
First Posted Date
2005-09-14
Last Posted Date
2013-05-20
Lead Sponsor
Eisai Inc.
Target Recruit Count
200
Registration Number
NCT00165841
Locations
🇺🇸

Quality Care Medical Center Inc., Vista, California, United States

A Study to Explore the Safety And Tolerability of Doses of E2007 Up to a Maximum of 8 mg In Patients With Parkinson's Disease Who Experience End-of-Dose Wearing Off Motor Fluctuations

Phase 2
Completed
Conditions
Parkinson's Disease
First Posted Date
2005-09-14
Last Posted Date
2015-06-02
Lead Sponsor
Eisai Inc.
Target Recruit Count
75
Registration Number
NCT00165789
Locations
🇺🇸

Raleigh Neurology Associates, Southfield, Michigan, United States

🇺🇸

Agape Medical Research Center, Piscataway, New Jersey, United States

🇺🇸

Clinical Trials Incorporated, Little Rock, Arkansas, United States

and more 6 locations

Efficacy and Safety Study of E2007 in Migraine Prophylaxis

Phase 2
Completed
Conditions
Migraine Prophylaxis
Interventions
Other: Placebo
First Posted Date
2005-09-12
Last Posted Date
2015-06-08
Lead Sponsor
Eisai Inc.
Target Recruit Count
206
Registration Number
NCT00154063
Locations
🇺🇸

Investigational Site, Houston, Texas, United States

🇺🇸

Elkind Headache Center, Mount Vernon, New York, United States

E2007 Given as Adjunctive Therapy in Patients With Refractory Partial Seizures

Phase 2
Completed
Conditions
Epilepsy
First Posted Date
2005-09-05
Last Posted Date
2015-11-03
Lead Sponsor
Eisai Inc.
Registration Number
NCT00144690
Locations
🇺🇸

Clinical Trials, Detroit, Michigan, United States

🇺🇸

Dept. of Neuro Surgery, Little Rock, Arkansas, United States

🇺🇸

Vanderbilt University Medical Ctr., Nashville, Tennessee, United States

and more 2 locations

Treatment of Gastroesophageal Reflux Disease in 12-16 Year Old Patients With Rabeprazole

Phase 2
Completed
Conditions
Gastroesophageal Reflux Disease
First Posted Date
2005-08-22
Last Posted Date
2009-12-03
Lead Sponsor
Eisai Inc.
Target Recruit Count
111
Registration Number
NCT00132496
Locations
🇺🇸

Marshall University, Huntington, West Virginia, United States

🇺🇸

Professional Clinical Research, Cadillac, Michigan, United States

🇺🇸

University of Pediatrics, Mason, Ohio, United States

and more 22 locations
© Copyright 2025. All Rights Reserved by MedPath